Communiqués Iterum Therapeutics plc

Actions

ITRMF

IE000TTOOBX0

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 21:19:54 08/09/2026			Varia. 5j.	Varia. 1 janv.
0,000001 ^USD	0,00%		0,00%	-100,00%

16/04	Eton Pharmaceuticals, Inc. nomme Judith "Judy" M. Matthews au poste de vice-présidente exécutive, comptabilité et finance	CI
27/03	Iterum sollicite sa dissolution judiciaire face à une impasse de trésorerie	RE

Communiqués

30/03	Stocks Under $0.10: ITRM, AMLM, BFRG, QNCX, ADMQ March Madness Watch	AQ
27/03	Iterum Therapeutics Announces Filing of Winding Up Petition	AQ
13/02	Iterum Therapeutics Provides Business Update	AQ
23/12	Iterum Therapeutics Provides Business Update	AQ
17/12	Iterum Therapeutics Provides Business Update	AQ
05/12	Iterum Therapeutics Provides Business Update	AQ
24/11	Iterum Therapeutics Provides Business Update	AQ
14/11	Iterum Therapeutics : Earnings Release Q3 2025	PU
14/11	Iterum Therapeutics Reports Third Quarter 2025 Financial Results	AQ
07/11	Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025	AQ
14/10/25	Iterum Therapeutics to Present Data at IDWeek 2025	AQ
19/09/25	Iterum Therapeutics Provides Business Update	AQ
20/08/25	Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.	AQ
05/08/25	Iterum Therapeutics Reports Second Quarter 2025 Financial Results	AQ
29/07/25	Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025	AQ
02/07/25	Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
30/06/25	Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth	AQ
25/06/25	Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence	AQ
11/06/25	Iterum Therapeutics Announces Partnership for Commercialization Services	AQ
19/05/25	Iterum Therapeutics Announces Extension of Term of Promissory Note	AQ
13/05/25	Iterum Therapeutics Reports First Quarter 2025 Financial Results	AQ
06/05/25	Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025	AQ
29/04/25	Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares	AQ
14/04/25	Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics	AQ
10/02/25	Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results	AQ